REGN FY 2012 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$79B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.4B+209.2% YoY

Gross Profit

$1.3B91.2% margin

Operating Income

$461M33.4% margin

Net Income

$750M54.4% margin

EPS (Diluted)

$6.75

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$124M

Stock-Based Comp.

$94M

Balance Sheet

Total Assets

$2.1B

Total Liabilities

$835M

Stockholders' Equity

$1.2B

Cash & Equivalents

$230M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.4B	$446M	+209.2%
Gross Profit	$1.3B	$411M	+206.2%
Operating Income	$461M	-$205M	+324.5%
Net Income	$750M	-$222M	+438.3%